India, Oct. 29 -- Bicycle Therapeutics plc (BCYC) reported third-quarter 2026 financial results and highlighted pipeline progress, including FDA Orphan Drug Designation for its investigational pancreatic cancer candidate, nuzefatide pevedotin.
Nuzefatide pevedotin, an EphA2-targeting Bicycle Drug Conjugate, is being evaluated in a Phase 2 trial in adults with recurrent pancreatic ductal adenocarcinoma (PDAC).
The company expects to provide further clinical updates in 2027.
The FDA designation offers development incentives, including potential tax credits for qualified clinical trial costs, exemption from certain user fees and the possibility of seven years of market exclusivity following approval.
Bicycle Therapeutics expects to initiat...